Phaseline

Companies › Elion Therapeutics

Elion Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EL219
Antifungal agent for early antifungal therapy of invasive mould infections
–Phase 2Invasive Mould InfectionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07215273EL219Phase 2Invasive Mould InfectionInfectious diseaseDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma Frantz Viral Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.